Is There a Role for Sodium Fluoride in Otosclerosis Treatment?

Area of Science:

• Otolaryngology
• Pharmacology
• Audiology

Background:

• Otosclerosis is a common cause of conductive hearing loss, but can also affect sensorineural hearing.
• Sodium fluoride (NaF) has been investigated for its potential to stabilize sensorineural hearing loss (SNHL) in otosclerosis.
• Current clinical guidelines and consensus on NaF use for otosclerosis are lacking.

Purpose of the Study:

• To interpret existing literature on sodium fluoride (NaF) for otosclerosis.
• To determine evidence-based best practices for NaF utilization in managing otosclerosis.
• To address the absence of established guidelines for NaF in otosclerosis treatment.

Main Methods:

• Systematic literature review of studies investigating NaF and otosclerosis.
• Analysis of clinical trial data and case reports on NaF efficacy and safety.
• Synthesis of findings to identify optimal treatment protocols.

Main Results:

• Evidence suggests NaF may stabilize or slow the progression of SNHL in some otosclerosis patients.
• Optimal dosage and duration of NaF treatment remain variable across studies.
• Potential side effects and long-term safety profile require further investigation.

Conclusions:

• NaF shows promise as an adjunctive therapy for stabilizing SNHL in otosclerosis.
• Standardized guidelines for NaF use in otosclerosis are needed.
• Further research is warranted to confirm efficacy, optimal dosing, and safety.